Aromatase inhibitors are the gold standard in the treatment of hormone receptor‐positive
breast cancer, but lead to an arthralgia syndrome which is implicated in 13–22% of …

Aromatase inhibitors (AIs) are the first-line treatment in women with breast cancer for total
estrogen depletion. Half the treated women may develop pain, and this condition may …

Women with hormone-dependent breast cancer are treated with aromatase inhibitors (AI) to
slow disease progression by decreasing estrogen levels. However, AI have adverse effects …

Background This prospective study evaluated the relationship between arthralgia and
compliance during the first year of adjuvant anastrozole therapy in postmenopausal women …

Background National guidelines suggest that women with hormone receptor positive breast
cancer be considered for adjuvant endocrine treatment with an aromatase inhibitor (AI) …

Résumé Introduction En Europe, le cancer du sein est le cancer le plus répandu chez les
femmes. Son traitement (TTT) peut avoir un retentissement important sur la vie quotidienne …

Résumé Les traitements médicamenteux du cancer s' ils permettent de plus en plus de
rémissions partielles ou totales peuvent provoquer une altération de la qualité de vie du …

Third-generation aromatase inhibitors (AIs) used in the treatment of hormone-responsive
breast cancer are associated with arthralgia, which is the most common reason for treatment …

Results: The average age of the patients‟ sample was 26-43. Amongst the studied
aspects,“fear” was the most negatively impacted; spiritual, physical, and social well-being …

Arthralgia is defined as non-inflammatory joint pain, whereas arthritis describes
inflammatory joint pain. This distinction is paramount in a breast cancer survivor, as the …